Woebot

Developed by Stanford psychologists, Woebot is an innovative AI chatbot that delivers cognitive behavioral therapy (CBT) techniques through conversational interactions. A randomized controlled trial published in JMIR Mental Health demonstrated that Woebot significantly reduced depression symptoms in just two weeks. Unlike many generic chatbots, Woebot's responses are firmly rooted in evidence-based CBT, DBT, and interpersonal psychotherapy frameworks, providing a more structured and effective experience. This free app is available 24/7, offering non-judgmental support for users at any time, a level of immediate access that outperforms scheduled therapy appointments. The FDA recognized its potential by granting it Breakthrough Device designation in 2023.